유두암과 여포 암에서 p53, Cylcin D1, Galectin-3 발현의 상관 관계
Correlation of Expression of p53, Cylcin D1 and Galectin-3 in Papillary Carcinoma and Follicular Carcinoma
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The thyroid is the organ that has the greatest risk of malignant tumors among the endocrine tumors. The papillary carcinoma occupies 80% of the entire thyroid tumors. Immunohistochemical staining of galectin-3 has usually been used in differentiating papillary carcinoma and follicular carcinoma. The p53 gene of the cell cycle is a tumor suppressor gene acting in on the control points. The cyclin D1 genes in the cell cycle, involved in the implementation of G1 and S phase, plays an important role in the progression of thyroid tumors. This research compares and analyzes correlation between papillary carcinoma, follicular carcinoma, p53, cyclin D1 and galectin-3 gene expression patterns. In a total of 30 cases from papillary carcinoma, 21 cases from p53 (70%), 27 cases in galectin-3 (90%), and 26 cases in cyclin D1 (86.7%) showed positive rate. The galectin-3 staining investigated, showed a significant difference between a papillary carcinoma and a follicular carcinoma. Follicular carcinoma from 15 cases, p53 in 13 cases (86.7%), galectin-3 in 5 cases (33.3%) and cyclin D1 in 12 cases (80%) showed a positive rate. The cyclin D1 in follicular carcinoma and staining between the p53 that had correlation was also investigated. In this study, as the examples of the expression of the 27 cases of galectin-3 (90%) in papillary carcinoma and 5 cases in follicular carcinoma (33.3%) indicate, it was concluded that there is a difference in the expression on both carcinoma. In addition, cyclin D1 and p53 has a positive rate in follicular carcinoma, when cyclin D1 in 12 cases (80%), there was a significant correlation that was investigated. Distinguishing between papillary carcinoma and follicular carcinoma can be identified by the expression of galectin-3. It is considered to get results that are more accurate in follicular carcinoma diagnosis depending on whether the cyclin D1 and p53 is expressed or not.
Abstract
The thyroid is the organ that has the greatest risk of malignant tumors among the endocrine tumors. The papillary carcinoma occupies 80% of the entire thyroid tumors. Immunohistochemical staining of galectin-3 has usually been used in differentiating papillary carcinoma and follicular carcinoma. The p53 gene of the cell cycle is a tumor suppressor gene acting in on the control points. The cyclin D1 genes in the cell cycle, involved in the implementation of G1 and S phase, plays an important role in the progression of thyroid tumors. This research compares and analyzes correlation between papillary carcinoma, follicular carcinoma, p53, cyclin D1 and galectin-3 gene expression patterns. In a total of 30 cases from papillary carcinoma, 21 cases from p53 (70%), 27 cases in galectin-3 (90%), and 26 cases in cyclin D1 (86.7%) showed positive rate. The galectin-3 staining investigated, showed a significant difference between a papillary carcinoma and a follicular carcinoma. Follicular carcinoma from 15 cases, p53 in 13 cases (86.7%), galectin-3 in 5 cases (33.3%) and cyclin D1 in 12 cases (80%) showed a positive rate. The cyclin D1 in follicular carcinoma and staining between the p53 that had correlation was also investigated. In this study, as the examples of the expression of the 27 cases of galectin-3 (90%) in papillary carcinoma and 5 cases in follicular carcinoma (33.3%) indicate, it was concluded that there is a difference in the expression on both carcinoma. In addition, cyclin D1 and p53 has a positive rate in follicular carcinoma, when cyclin D1 in 12 cases (80%), there was a significant correlation that was investigated. Distinguishing between papillary carcinoma and follicular carcinoma can be identified by the expression of galectin-3. It is considered to get results that are more accurate in follicular carcinoma diagnosis depending on whether the cyclin D1 and p53 is expressed or not.
참고문헌 (13)
- Bartolazzi A, "Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesion", Lancet, 357, pp.1644~1650 (2001)
- Davies L, "Increasing incidence of thyroid cancer in the United States, 1973-2002", JAMA, 295, pp.2164~2167 (2006)
- Harris CC, "Clinical implications of the p53 tumorsuppressor gene", N Engl J Med, 329, pp.1318~1327 (1993)
- Kastan MB, "A mammalian cell cycle check-point pathway utilizing p53 and GADD45 is defective in ataxia-telangietasia", Cell, 71, pp.587~597 (1992)
- Kang YK, "Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4", Dpc4 in intrahepatic cholangiocarcinoma, 2002, pp.33, 877~883
- Kim KR, "Cell cycle arrest and inhibition of anoikis by galectin-3 in hyman breast epithelial cells", Cancer Res, 59, pp.4148~4154 (1999)
- Lazzereschi D, "Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinoma", Int J Cancer, 76, pp.806~811 (1998)
- Leenhardt L, "Increase incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effect: Report from the French Thyroid Cancer Committee", Thyroid, 14, pp.1056~1060 (2004)
- Livingstone LR, "Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53", Cell, 70, pp.923~935 (1992)
- Orlandi F, "Galectin-3 is a presurgical marker of human thyroid carcinoma", Cancer Res, 58, pp.3015~3020 (1998)
- Papotti M, "Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma", Eur J Endocrinol, 147, pp.515~521 (2002)
- Semenov Dlu, "Galectin-3 in diagnosis of thyroid cancer", Vopr Onkol, 54, pp.321~323 (2008)
- Wang S, "The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer", Mod Pathol, 13, pp.882~887 (2000)